A Phase III trial found that a three-drug combination — adding bortezomib to the standard therapy of lenalidomide and dexamethasone — extended multiple myeloma remissions by one year and added another year of survival, compared to the two-drug therapy alone.
Researchers found that patients who received the bortezomib combination lived a median of 75 months after their initial six-month treatment. The study was sponsored by the International Myeloma Foundation and SWOG, a publically funded trials network. The results were published in The Lancet.
Lenalidomide is an immunomodulating therapy marketed as Revlimid by Celgene. Bortezomib is a proteasome inhibitor marketed as Velcade by Millennium Pharmaceuticals.